ATE362760T1 - Heterocyclen enthaltende biphenyl-ap2-inhibitoren und ein verfahren - Google Patents

Heterocyclen enthaltende biphenyl-ap2-inhibitoren und ein verfahren

Info

Publication number
ATE362760T1
ATE362760T1 AT00918177T AT00918177T ATE362760T1 AT E362760 T1 ATE362760 T1 AT E362760T1 AT 00918177 T AT00918177 T AT 00918177T AT 00918177 T AT00918177 T AT 00918177T AT E362760 T1 ATE362760 T1 AT E362760T1
Authority
AT
Austria
Prior art keywords
biphenyl
containing heterocycles
inhibitors containing
inhibitors
heterocycles
Prior art date
Application number
AT00918177T
Other languages
English (en)
Inventor
Jeffrey Robl
Richard Sulsky
David Magnin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE362760T1 publication Critical patent/ATE362760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT00918177T 1999-04-05 2000-03-20 Heterocyclen enthaltende biphenyl-ap2-inhibitoren und ein verfahren ATE362760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12774599P 1999-04-05 1999-04-05

Publications (1)

Publication Number Publication Date
ATE362760T1 true ATE362760T1 (de) 2007-06-15

Family

ID=22431728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918177T ATE362760T1 (de) 1999-04-05 2000-03-20 Heterocyclen enthaltende biphenyl-ap2-inhibitoren und ein verfahren

Country Status (32)

Country Link
US (2) US6548529B1 (de)
EP (1) EP1181014B1 (de)
JP (1) JP2002541106A (de)
KR (1) KR20010108457A (de)
CN (1) CN1345239A (de)
AR (1) AR023388A1 (de)
AT (1) ATE362760T1 (de)
AU (1) AU3903600A (de)
BG (1) BG105968A (de)
BR (1) BR0009563A (de)
CA (1) CA2366871A1 (de)
CO (1) CO5160302A1 (de)
CZ (1) CZ20013542A3 (de)
DE (1) DE60034945T2 (de)
EE (1) EE200100504A (de)
ES (1) ES2287003T3 (de)
HK (1) HK1042848A1 (de)
HU (1) HUP0202251A3 (de)
ID (1) ID30322A (de)
IL (1) IL144879A0 (de)
LT (1) LT4921B (de)
LV (1) LV12782B (de)
MX (1) MXPA01009984A (de)
NO (1) NO20014823D0 (de)
NZ (1) NZ513493A (de)
PE (1) PE20001646A1 (de)
PL (1) PL350900A1 (de)
SK (1) SK13152001A3 (de)
TR (1) TR200102874T2 (de)
UY (1) UY26093A1 (de)
WO (1) WO2000059506A1 (de)
ZA (1) ZA200106856B (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
CA2390923A1 (en) 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
DE60121988T2 (de) 2000-10-30 2007-02-15 Ortho-Mcneil Pharmaceutical, Inc. Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
EP1343763A1 (de) 2000-11-20 2003-09-17 Bristol-Myers Squibb Company Pyrodon-derivate als ap2 inhibitoren
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
WO2003006023A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Company Pyrazinone inhibitors of fatty acid binding protein and method
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (de) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co Doppelte hemmer des adipozyten-fettsäure-bindungsproteins und des keratinozyten-fettsäure-bindungsproteins
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
CN1659131A (zh) 2002-04-08 2005-08-24 葛兰素集团有限公司 2－((2－烷氧基)－苯基)－环戊－1－烯基)芳香碳－以及杂环羧酸及其衍生物
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US6861553B2 (en) * 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
JP2006501263A (ja) * 2002-09-09 2006-01-12 アムジエン・インコーポレーテツド 炎症治療用のＴＮＦ−αおよびインターロイキン低下剤としての１，４，５−置換１，２−ジヒドロ−ピラゾール−３−オンおよび３−アルコキシ−１Ｈ−ピラゾール誘導体
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1567487A4 (de) * 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
US7300639B2 (en) 2002-12-03 2007-11-27 Bristol-Myers Squibb Company Process for removing metals from liquids
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
AP2103A (en) * 2003-01-23 2010-02-08 Shire Holdings Ag A skin permeable form of an anagrelide and device therefore
EP1594854B1 (de) 2003-02-06 2010-09-01 Bristol-Myers Squibb Company Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004084890A1 (en) * 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1617840A4 (de) 2003-05-01 2008-08-20 Bristol Myers Squibb Co Pyrazole-amid-verbindungen als kinase-hemmer
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (es) * 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7317032B2 (en) * 2003-09-02 2008-01-08 Bristol-Myers Squibb Co. Imidazolyl inhibitors of 15-lipoxygenase
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004288831B2 (en) 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
CA2565628A1 (en) * 2004-05-03 2005-11-10 Astellas Pharma Inc. The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7754755B2 (en) * 2004-09-23 2010-07-13 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US8143425B2 (en) * 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1879881A2 (de) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitoren der 11-beta-hydroxysteroiddehydrogenase vom typ i
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
CN1903364B (zh) * 2005-07-26 2011-06-22 安徽省现代中药研究中心 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
EP1757290A1 (de) 2005-08-16 2007-02-28 Zentaris GmbH Triazolderivate als Liganden der Wachstumshormonrezeptoren
US7534804B2 (en) * 2005-08-24 2009-05-19 Bristol-Myers Squibb Company Benzoxazole inhibitors of 15-lipoxygenase
WO2007033265A1 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
GEP20135791B (en) * 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
NZ566799A (en) * 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en) * 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
EP2487154B1 (de) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl-beta-amino-amid-basierte Inhibitoren von Dipeptidylpeptidase IV und Verfahren
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1999108A1 (de) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Herstellung von (r)-3-aminopiperidin-dihydrochlorid
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP1889617A1 (de) * 2006-07-11 2008-02-20 Freie Universität Berlin Triphenylsubstituierte fünfgliedrige Heterocyclen und deren Verwendung als Antikreb- und entzündungshemmende Mittel
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
PL2073810T3 (pl) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
US8222285B2 (en) 2007-06-11 2012-07-17 Bristol-Myers Squibb Company 1,3-dihydroxy substituted phenylamide glucokinase activators
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2238128B1 (de) 2007-12-26 2012-08-22 Sanofi Heterocyclische pyrazolcarboxamide als p2y12-antagonisten
WO2009097596A1 (en) * 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) * 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
EP2103602A1 (de) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Neuartige 1,2,4-Triazol-Derivate und Herstellungsverfahren dafür
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP2010150200A (ja) * 2008-12-25 2010-07-08 Tosoh Corp イミダゾール化合物およびその製造方法
WO2010083532A1 (en) 2009-01-19 2010-07-22 The Research Foundaton Of State University Of New York Fatty acid binding proteins as drug targets for modulation of endocannabinoids
PT2403605E (pt) * 2009-03-05 2015-08-05 Harvard College Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
BR112012011274A2 (pt) 2009-11-13 2016-04-12 Astrazeneca Uk Ltd formulação de metformina de massa reduzida e sua combinação
CN102711739B (zh) 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
EP2558461B1 (de) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (de) 2010-04-23 2015-10-28 Cytokinetics, Inc. Bestimmte aminopyrimidine und aminotriazine, zusammensetzungen daraus und verfahren zu ihrer verwendung
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2600716A4 (de) 2010-08-03 2014-02-19 Beth Israel Hospital Verfahren und zusammensetzungen zur behandlung von stoffwechselerkrankungen
CN103370064A (zh) 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2431035A1 (de) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Neue Triazolderivate mit verbesserter Rezeptoraktivität und Bioverfügbarkeitseigenschaften als Ghrelin-Antagonisten der Wachstumshormon-Sekretagogum-Rezeptoren
JP5629380B2 (ja) 2010-12-17 2014-11-19 田辺三菱製薬株式会社 連続芳香環式化合物
AU2012212448B9 (en) 2011-02-01 2015-06-25 Astrazeneca Uk Limited Pharmaceutical formulations including an amine compound
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
EP2867215B1 (de) * 2012-06-25 2018-07-18 Saniona A/S Tetrazol-derivate und deren verwendung als kaliumkanalmodulatoren
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3733170A1 (de) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Verfahren zur behandlung von androgenrezeptor(ar)-positivem brustkrebs mit selektivem androgenrezeptormodulator (sarms)
TR201908247T4 (tr) 2012-11-20 2019-06-21 Lexicon Pharmaceuticals Inc Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
US11229624B2 (en) 2016-10-25 2022-01-25 Ticure Ltd. FABP4 as a therapeutic target in skin diseases
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
AU2018279950A1 (en) 2017-06-09 2020-01-30 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
EP4563150A3 (de) 2019-05-13 2025-07-23 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs
EP3990447A1 (de) 2019-06-27 2022-05-04 Cytokinetics, Inc. Polymorphe von 1-(2-(((trans)-3-fluor-1-(3-fluorpyridin-2-yl)butyl)methyl)amino) pyrimidin-5-yl)-1h-pyrrol-3-carboxamid
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
IL297333B2 (en) 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
AU2021297465A1 (en) 2020-06-27 2023-03-02 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2716882B1 (fr) 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5756527A (en) 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP1052994A2 (de) 1998-02-02 2000-11-22 Trustees Of Tufts College Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
EP1062222A1 (de) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Serin-peptidase modulatoren
WO1999058518A2 (en) 1998-05-12 1999-11-18 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000001679A1 (en) 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor regulators
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
EP2584011B1 (de) 2010-06-16 2018-06-20 Konica Minolta Holdings, Inc. Tintenstrahltinte und tintenstrahl-abbildungsverfahren damit
US9390275B1 (en) 2015-01-27 2016-07-12 Centurion Holdings I, Llc System and method for controlling hard drive data change

Also Published As

Publication number Publication date
ZA200106856B (en) 2002-11-20
DE60034945D1 (de) 2007-07-05
ES2287003T3 (es) 2007-12-16
LV12782A (en) 2002-01-20
AR023388A1 (es) 2002-09-04
NO20014823L (no) 2001-10-04
WO2000059506A8 (en) 2001-03-08
NZ513493A (en) 2004-02-27
KR20010108457A (ko) 2001-12-07
US6548529B1 (en) 2003-04-15
EE200100504A (et) 2002-12-16
HUP0202251A2 (hu) 2002-11-28
US6927227B2 (en) 2005-08-09
UY26093A1 (es) 2000-10-31
CA2366871A1 (en) 2000-10-12
CO5160302A1 (es) 2002-05-30
ID30322A (id) 2001-11-22
HK1042848A1 (zh) 2002-08-30
JP2002541106A (ja) 2002-12-03
CZ20013542A3 (cs) 2002-01-16
CN1345239A (zh) 2002-04-17
IL144879A0 (en) 2002-06-30
NO20014823D0 (no) 2001-10-04
AU3903600A (en) 2000-10-23
EP1181014A4 (de) 2002-06-05
US20030199563A1 (en) 2003-10-23
WO2000059506A1 (en) 2000-10-12
LT4921B (lt) 2002-06-25
EP1181014B1 (de) 2007-05-23
EP1181014A1 (de) 2002-02-27
BR0009563A (pt) 2002-01-15
SK13152001A3 (sk) 2002-04-04
MXPA01009984A (es) 2002-04-24
HUP0202251A3 (en) 2003-11-28
PE20001646A1 (es) 2001-04-07
LV12782B (en) 2002-06-20
LT2001092A (en) 2002-02-25
DE60034945T2 (de) 2008-01-17
BG105968A (en) 2002-05-31
PL350900A1 (en) 2003-02-10
TR200102874T2 (tr) 2002-03-21

Similar Documents

Publication Publication Date Title
DE60034945D1 (de) Heterocyclen enthaltende biphenyl-ap2-inhibitoren und ein verfahren
DE60120822D1 (de) Meta-Dokument und Verfahren zum Verwalten von Meta-Dokumenten
DE60013420D1 (de) Verfahren zum ringförmigen abdichten
DE69933888D1 (de) Ein gruppenkommunikationsgerät und verfahren
DE69814710D1 (de) Beschichtungs-Vorrichtung und Verfahren
DE60105477D1 (de) Beschichtungs-Vorrichtung und Verfahren
DE69834401D1 (de) Businterfacesystem und verfahren
DE60025693D1 (de) Gerät und Verfahren zur Erkennung der Ursache einer Teilentladung
NO20020753L (no) Fremgangsmåte og anordning for bestemmelse av en tidsparameter
DE69826167D1 (de) Verfahren und Gerät zur Graffitianimation
DE60026728D1 (de) Bauteilbestückungseinrichtung und verfahren
DE60044718D1 (de) Mehrfrequenz-multipol und verfahren zu seiner verwendung
DE69938638D1 (de) Diebstahlsicherungsetikett und verfahren zu seiner befestigung
DE59912231D1 (de) Verfahren zum Speichern von Positionsdaten
DE60142824D1 (de) Numerisch gesteuertes Verfahren
DE60106128D1 (de) Selbstklebendes Klebeband und Verfahren zu dessen Verwendung
DE60017429D1 (de) Teigformmaschine und verfahren
DE60123403D1 (de) Elektronisches gerät und verfahren zu dessen kontrolle
DE60033224D1 (de) Drucksystem und Verfahren dafür
DE69939152D1 (de) Speicherschnittstellenvorrichtung und Verfahren zum Speicherzugriff
DE60009503D1 (de) Verfahren und vorrichtung zum umwickeln
DE69905326D1 (de) Sollerschlitz und Verfahren zu dessen Herstellung
DE69922242D1 (de) Verfahren und vorrichtung zum aufwickeln von metallbändern
DE69914170D1 (de) Elektrofotografische Vorrichtung und Verfahren
DE69806673D1 (de) Magnetrongerät und Verfahren zu dessen Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181014

Country of ref document: EP